Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, Hasbini A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Lange C, Phan L, Belhouari H, Tran Y, Kotti S, Helissey C. Oudard S, et al. Among authors: ratta r. JAMA Oncol. 2023 Dec 1;9(12):1629-1638. doi: 10.1001/jamaoncol.2023.4255. JAMA Oncol. 2023. PMID: 37883073
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.
Vauchier C, Auclin E, Barthélémy P, Carril-Ajuria L, Ryckewaert T, Borchiellini D, Castel-Ajgal Z, Bennamoun M, Campedel L, Thiery-Vuillemin A, Coquan E, Crouzet L, Berdah JF, Chevreau C, Ratta R, Fléchon A, Lefort F, Albiges L, Gross-Goupil M, Vano YA, Thibault C, Oudard S. Vauchier C, et al. Among authors: ratta r. J Oncol. 2022 Feb 18;2022:3449660. doi: 10.1155/2022/3449660. eCollection 2022. J Oncol. 2022. PMID: 35222642 Free PMC article.
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K. Aldea M, et al. Among authors: ratta r. Eur J Cancer. 2021 Dec;159:87-97. doi: 10.1016/j.ejca.2021.09.029. Epub 2021 Nov 2. Eur J Cancer. 2021. PMID: 34742160
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Vano YA, Phan L, Gravis G, Korakis I, Schlürmann F, Maillet D, Bennamoun M, Houede N, Topart D, Borchiellini D, Barthelemy P, Ratta R, Ryckewaert T, Hasbini A, Hans S, Emambux S, Cournier S, Braychenko E, Elaidi RT, Oudard S. Vano YA, et al. Among authors: ratta r. Int J Cancer. 2022 Oct 15;151(8):1335-1344. doi: 10.1002/ijc.34126. Epub 2022 Jun 6. Int J Cancer. 2022. PMID: 35603906 Free PMC article.
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
Epaillard N, Parent P, Loriot Y, Lavaud P, Vera-Cea EB, Martinez-Chanza N, Rodriguez-Vida A, Dumont C, Lozano R, Llácer C, Ratta R, Oudard S, Thibault C, Auclin E. Epaillard N, et al. Among authors: ratta r. Front Oncol. 2021 May 20;11:671969. doi: 10.3389/fonc.2021.671969. eCollection 2021. Front Oncol. 2021. PMID: 34094973 Free PMC article.
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, Maillard A, Martineau G, Borget I, Fizazi K; Groupe d’Etude des Tumeurs Uro-Genitales (GETUG).. Baciarello G, et al. Among authors: ratta r. Eur Urol. 2022 Mar;81(3):234-240. doi: 10.1016/j.eururo.2021.10.016. Epub 2021 Nov 14. Eur Urol. 2022. PMID: 34789394 Clinical Trial.
Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L, Colomba E, Romero-Ferreiro C, Cerbone L, Ratta R, Barthelemy P, Vindry C, Fléchon A, Cherifi F, Boughalem E, Linassier C, Fornarini G, Rebuzzi SE, Gross-Goupil M, Saldana C, Martin-Soberón M, de Velasco G, Manneh R, Pernaut C, Sanchez de Torre A, Flippot R, Escudier B, Albiges L. Carril-Ajuria L, et al. Among authors: ratta r. Eur J Cancer. 2023 Feb;180:21-29. doi: 10.1016/j.ejca.2022.11.013. Epub 2022 Nov 26. Eur J Cancer. 2023. PMID: 36527973
56 results